Anixa Biosciences, Inc.
NASDAQ:ANIXBiotechnology
+$0.10 today
- Market cap
- $94.21M
- Beta
- 0.60
- P/E (TTM)
- -9.3
- EPS (TTM)
- -$0.30
Volume 0.29M
Average 0.12M
ANIX Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Anixa Biosciences, Inc.NASDAQ: ANIX
Retained Earnings · Q2 FY2026 · quarter ended Apr 2026
Retained earnings remains negative
Q2 FY2026 retained earnings was -$256.76M, compared with -$246.72M a year earlier.
Context
- Retained earnings amounted to 1727.3% of total assets at the end of Q2 FY2026, up 274.0 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -4.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (251.68M) USD
- Year-over-year change
- -4.5%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-31 | (251.68M) | -4.5% |
| FY2024 | 2024-10-31 | (240.75M) | -5.5% |
| FY2023 | 2023-10-31 | (228.2M) | -4.5% |
| FY2022 | 2022-10-31 | (218.39M) | -6.6% |
| FY2021 | 2021-10-31 | (204.79M) | — |
Retained Earnings vs competitors
How ANIX compares with its peers on the latest reported figures
- ANIX's Apr 2026 retained earnings of -$256.76M is the 5th highest of the 10 companies compared; the peer median is -$458.27M.
- Its year-over-year change of -4.1% is the 3rd highest of 10, against a peer median of -15.5%.
- Retained earnings amounts to 1727.3% of total assets for ANIX, versus a peer median of 776.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$128.87M | -10.6% | — | 981.6% | |
| Mar 2026 | -$148.72M | -26.3% | — | 500.7% | |
ACTUActuate Therapeutics Inc | Mar 2026 | -$160.23M | -15.5% | — | 1798.1% |
IRDOpus Genetics, Inc. | Mar 2026 | -$254.12M | -72.6% | — | 380.5% |
| Apr 2026 | -$256.76M | -4.1% | — | 1727.3% | |
| Mar 2026 | -$458.27M | +3.2% | — | 776.5% | |
| Mar 2026 | -$467.2M | -32.0% | — | 349.6% | |
| Mar 2026 | -$482.81M | -17.1% | — | 177.4% | |
| Mar 2026 | -$1.83B | -4.9% | — | 3686.1% | |
| Mar 2026 | -$2.14B | +2.9% | — | 1149.6% | |
| Peer median (excluding ANIX) | -$458.27M | -15.5% | — | 776.5% | |
Competitors are the stored peer set for ANIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 29.13M | 12.36M | 915K | 1.27M | 1.24M |
| Short-term Investments | 6.6M | 17.33M | 22.93M | 18.65M | 13.93M |
| Net Receivables | 0 | 46K | 270K | 173K | 0 |
| Inventory | 0 | (46K) | 0 | 0 | 0 |
| Other Current Assets | (444) | 46K | 1.24M | 1.27M | 713K |
| Total Current Assets | 36M | 30.2M | 25.36M | 21.36M | 15.89M |
| Property, Plant & Equipment (Net) | 253.96K | 212K | 166K | 229K | 193K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 253.96K | 212K | 166K | 229K | 193K |
| Total Assets | 36.26M | 30.41M | 25.52M | 21.59M | 16.08M |
| Account Payables | 136K | 265K | 206K | 525K | 165K |
| Short-term Debt | 0 | 0 | 0 | 0 | 41K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 922K |
| Total Current Liabilities | 1.27M | 2.04M | 2.03M | 2.5M | 1.97M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 82 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 220.08K | 175K | 123K | 203K | 163K |
| Total Liabilities | 1.49M | 2.21M | 2.15M | 2.7M | 2.13M |
| Common Stock | 300.51K | 309K | 311K | 322K | 330K |
| Retained Earnings | (204.79M) | (218.39M) | (228.2M) | (240.75M) | (251.68M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | (670.51K) | (847K) | (966K) | (1.11M) | (1.21M) |
| Total Equity | 34.77M | 28.2M | 23.37M | 18.89M | 13.95M |
| Total Debt | 259K | 221K | 175K | 232K | 204K |
| Net Debt | (28.83M) | (12.14M) | (740K) | (1.04M) | (1.04M) |
Anixa Biosciences, Inc.
NASDAQ:ANIX
Intrinsic Alpha fair value
Locked
Current Price
$2.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.